Ubs Oconnor LLC Monte Rosa Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.5 - $5.93 $103,077 - $244,499	-41,231 Reduced 48.24%	44,247 $249,000
Q3 2023 Nov 14, 2023	SELL	$4.78 - $7.22 $71,700 - $108,300	-15,000 Reduced 14.93%	85,478 $409,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $8.4 $455,165 - $844,015	100,478 New	100,478 $688 Million
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $27,066 - $37,347	4,549 Added 5.0%	95,528 $744,000
Q4 2022 Feb 14, 2023	SELL	$6.71 - $9.72 $4,267 - $6,181	-636 Reduced 0.69%	90,979 $0
Q3 2022 Nov 14, 2022	SELL	$7.17 - $12.16 $71,929 - $121,989	-10,032 Reduced 9.87%	91,615 $748 Million
Q2 2022 Aug 12, 2022	BUY	$6.15 - $14.99 $213,079 - $519,358	34,647 Added 51.71%	101,647 $982,000
Q1 2022 May 16, 2022	BUY	$10.36 - $20.41 $694,120 - $1.37 Million	67,000 New	67,000 $939,000

43.9M

141K

31.2K

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $329M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.